Exploring natural products as Bcl-2 inhibitors for acute myeloid leukemia therapy using In vitro, STD-NMR spectroscopy, and In silico approaches | Synapse
March 3, 2026
Exploring natural products as Bcl-2 inhibitors for acute myeloid leukemia therapy using In vitro, STD-NMR spectroscopy, and In silico approaches
Key Points
Inhibition of Bcl-2 was confirmed through in vitro testing of various natural products, showing promising anti-leukemic effects.
The study utilized STD-NMR spectroscopy to characterize interactions between Bcl-2 and potential therapeutic agents.
In silico approaches helped predict how natural products can precisely target Bcl-2 and improve treatment outcomes.
Findings may enable the development of natural compound-based therapies for acute myeloid leukemia, requiring further clinical investigation.